Professor Andrew Hattersley FMedSci FRS
Professor Andrew Hattersley FMedSci FRS was awarded the 2016 Royal Society GlaxoSmithKline Prize and Lecture for his work on genetic and physiological studies of patients with common subtypes of monogenic diabetes revolutionising treatment for these patients.
Dr Nicholas Lydon FRS was awarded the 2014 Royal Society GlaxoSmithKline Prize and Lecture for the development of the drug imatinib, a targeted tyrosine kinase inhibitor that has transformed the treatment of chronic myelogenous leukaemia (CML) and is a paradigm for cancer drug discovery.
See full list of all past winners of the Royal Society GlaxoSmithKline Prize and Lecture.
The award was initially established following a donation from The Wellcome Foundation. Since 2002 it has been supported by GlaxoSmithKline Limited. The first award was made in 1980.
The Royal Society GlaxoSmithKline Prize and Lecture is awarded biennially for 'original contributions to medical and veterinary sciences published within ten years from the date of the award'. There is no restriction on the nationality of the recipient.
The medal is of gold and is accompanied by a gift of £2,500. The award is normally made to one individual and the winner is called upon to deliver a lecture at the Society.
The call for nominations is now closed. The next call for nominations will open in November 2016.
The recipient is chosen by the Council of the Royal Society on the recommendation of the Biological Sciences Award Committee. The committee will consider the nomination a maximum of 3 times, before the nomination is retired. Re-nomination is possible after 1 round has passed. Employees of GlaxoSmithKline are not eligible for the award.
This award is supported by GlaxoSmithKline Limited.